A Rapid Nucleic Acid Amplification Test-Based, Conditional Release-to-Work Policy for Health Care Personnel With Symptoms Consistent With COVID-19
- PMID: 36240750
- PMCID: PMC9897112
- DOI: 10.1097/JOM.0000000000002733
A Rapid Nucleic Acid Amplification Test-Based, Conditional Release-to-Work Policy for Health Care Personnel With Symptoms Consistent With COVID-19
Abstract
Objective: Most health care personnel (HCP) reporting symptoms consistent with COVID-19 illness are assessed by high-accuracy SARS-CoV-2 assays performed in clinical laboratories, but the results of such assays typically are not available until the following day.
Methods: This is an observational study over 16 weeks of a rapid nucleic acid amplification test (NAAT) performed at point of contact. The benchmark for comparison was a simultaneously obtained specimen assayed by a routine NAAT assay performed in a clinical laboratory.
Results: There were 577 paired rapid and routine NAAT results. Rapid test positive predictive value was 90.0% (95% confidence interval = 88.8%-91.2%), and negative predictive value was 95.2% (95% confidence interval = 93.5%-96.9%). The rapid test avoided an estimated 160 to 184 lost work shifts over 4 months.
Conclusions: A rapid NAAT test-based strategy proved effective in safely clearing symptomatic employees without infection for earlier return to work.
Copyright © 2022 American College of Occupational and Environmental Medicine.
Conflict of interest statement
Conflict of Interest: None declared.
Similar articles
-
Sensitivity and Diagnostic Yield of the First SARS-CoV-2 Nucleic Acid Amplification Test Performed for Patients Presenting to the Hospital.JAMA Netw Open. 2022 Oct 3;5(10):e2236288. doi: 10.1001/jamanetworkopen.2022.36288. JAMA Netw Open. 2022. PMID: 36223119 Free PMC article.
-
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.Trials. 2021 Jan 8;22(1):39. doi: 10.1186/s13063-020-04982-z. Trials. 2021. PMID: 33419461 Free PMC article.
-
Comparison of an ID NOW COVID-19 Assay Used at the Point of Care to Laboratory-Based Nucleic Acid Amplification Tests.J Clin Microbiol. 2023 Jul 20;61(7):e0041323. doi: 10.1128/jcm.00413-23. Epub 2023 Jul 3. J Clin Microbiol. 2023. PMID: 37395672 Free PMC article.
-
Advances in nucleic acid amplification techniques (NAATs): COVID-19 point-of-care diagnostics as an example.Biosens Bioelectron. 2022 Jun 15;206:114109. doi: 10.1016/j.bios.2022.114109. Epub 2022 Feb 26. Biosens Bioelectron. 2022. PMID: 35245867 Review.
-
Strategies That Facilitate Extraction-Free SARS-CoV-2 Nucleic Acid Amplification Tests.Viruses. 2022 Jun 15;14(6):1311. doi: 10.3390/v14061311. Viruses. 2022. PMID: 35746782 Free PMC article. Review.
Cited by
-
Laboratory-based molecular test alternatives to RT-PCR for the diagnosis of SARS-CoV-2 infection.Cochrane Database Syst Rev. 2024 Oct 14;10(10):CD015618. doi: 10.1002/14651858.CD015618. Cochrane Database Syst Rev. 2024. PMID: 39400904
References
-
- FDA . SARS-CoV-2 reference panel comparative data. Posted 12/7/2020. Available at: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-dev.... Accessed August 6, 2022.